C71T
CANCELLED SECTION 71
06/03/2026
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Tipo de processo
Eventos registrados
Atualização mais recente
Classificação
Tipo de marca
Classes Nice
Data de depósito
Data de registro
Data de expiração
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
Última transação
Escritório responsável
Código da situação
Cadastro oficial
Código do desenho
Tipo de titular
Localização do titular
Examinador
Unidade examinadora
Descrição da marca
The mark consists of the literal stylized wording "gmp orphan drugs for orphan diseases". The wording "gmp" and "drugs for orphan diseases" appear in the color white, and the wording "orphan" is in black. The wording "gmp" is displayed with the letter "o" of the wording "orphan" above the wording "drugs for orphan diseases" all in a blue box, and the letters "rphan" appear outside of the box.
Titulares
Representantes
Heather Smith-Carra Banner & Witcoff, Ltd.
Classes Nice
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical and veterinary products for the treatment of orphan diseases; medication for the treatment of orphan diseases; pharmaceutical and veterinary products for pediatric use for the treatment of orphan diseases; medication for pediatric use for the treatment of orphan diseases; chemical preparations for medical or pharmaceutical use in the treatment of childhood diseases; pharmaceutical and veterinary products and medicines for the treatment of orphan diseases, particularly spinal muscular atrophy, sickle-cell anemia, progressive nuclear palsy, amyotrophic lateral sclerosis (ALS), cystic fibrosis, Duchenne muscular dystrophy, macrophagic myofasciitis, lysosomal storage disease, leukodystrophy; pharmaceutical and veterinary products and medicines for the treatment of hyperammonemia of all kinds
Classe 10
[ Medical, surgical and veterinary apparatus and instruments, for diagnosis and treatment, particularly in connection with orphan diseases; medical devices containing chemical products for diagnostic use of orphan diseases; medical diagnosis apparatus and instruments to diagnose orphan diseases; automatic testing apparatus to diagnose orphan diseases, for medical use, also in the form of kits; medical apparatus and instruments in the form of kits for detecting the presence of analytes in biological fluids, other fluids and other structures; immunochemical testing apparatus for medical use; blood testing apparatus; radiological apparatus for medical use; resuscitation apparatus; medical imaging apparatus incorporating medical imaging software; needles for medical use; gloves for medical use; syringes for medical use; inhalers for medical purposes; injectors for medical use; X-ray photographs for medical use; radiology screens for medical use; receptacles for applying medicines; containers especially made for medical waste; probes for medical use; stethoscopes; heart pacemakers; thermometers for medical use; cases fitted for medical instruments for use by surgeons or doctors ]
Classe 42
Evaluations, assessments and research in the fields of science; research and development services in the field of medicine; research and development of new products for others, namely, medical diagnosis apparatus; research and development in the field of biotechnology; scientific research for medical purposes; scientific laboratory services in the medical field; all the aforesaid services in connection with the treatment of childhood and orphan diseases, particularly spinal muscular atrophy, sickle-cell anemia, progressive nuclear palsy, amyotrophic lateral sclerosis (ALS), cystic fibrosis, Duchenne muscular dystrophy, macrophagic myofasciitis, lysosomal storage disease, leukodystrophy
Classe 44
Medical services; medical and sanitary care, namely, telemedecine services including remote diagnosis or medical follow-up; medical testing for the diagnosis and treatment of persons; providing medical advice on health matters in the field of medication administration; providing medical advisory services relating to medical apparatus and instruments; medical diagnosis services of orphan diseases; providing medical information, all the aforesaid services in connection with the treatment of childhood and orphan diseases, particularly spinal muscular atrophy, sickle-cell anemia, progressive nuclear palsy, amyotrophic lateral sclerosis (ALS), cystic fibrosis, Duchenne muscular dystrophy, macrophagic myofasciitis, lysosomal storage disease, leukodystrophy
Histórico de despachos e eventos da marca no USPTO.
42 publicações encontradas
CANCELLED SECTION 71
06/03/2026
INTERNATIONAL REGISTRATION RENEWED
09/06/2023
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
03/06/2023
PARTIAL INVALIDATION PROCESSED BY THE IB
05/12/2021
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
27/10/2021
INVALIDATION PROCESSED
27/10/2021
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
06/10/2021
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
06/02/2021
REGISTERED - PARTIAL SEC 71 ACCEPTED
06/02/2021
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
01/02/2021
CHANGE OF NAME/ADDRESS REC'D FROM IB
29/01/2021
TEAS SECTION 71 RECEIVED
03/12/2020
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
03/06/2019
NEW REPRESENTATIVE AT IB RECEIVED
07/02/2019
CHANGE OF NAME/ADDRESS REC'D FROM IB
08/02/2018
NEW REPRESENTATIVE AT IB RECEIVED
03/03/2016
FINAL DECISION TRANSACTION PROCESSED BY IB
21/11/2014
FINAL DISPOSITION NOTICE SENT TO IB
21/10/2014
FINAL DISPOSITION PROCESSED
21/10/2014
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
03/09/2014
REGISTERED-PRINCIPAL REGISTER
03/06/2014
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
18/03/2014
PUBLISHED FOR OPPOSITION
18/03/2014
NOTIFICATION PROCESSED BY IB
14/03/2014
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
26/02/2014
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
26/02/2014
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
26/02/2014
LAW OFFICE PUBLICATION REVIEW COMPLETED
07/02/2014
APPROVED FOR PUB - PRINCIPAL REGISTER
05/02/2014
TEAS/EMAIL CORRESPONDENCE ENTERED
05/02/2014
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/02/2014
ASSIGNED TO LIE
30/01/2014
TEAS RESPONSE TO OFFICE ACTION RECEIVED
22/01/2014
REFUSAL PROCESSED BY IB
30/09/2013
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
11/09/2013
REFUSAL PROCESSED BY MPU
11/09/2013
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
11/09/2013
NON-FINAL ACTION WRITTEN
10/09/2013
ASSIGNED TO EXAMINER
03/09/2013
APPLICATION FILING RECEIPT MAILED
16/08/2013
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/08/2013
SN ASSIGNED FOR SECT 66A APPL FROM IB
08/08/2013
Proteção contínua da sua marca
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.